| Literature DB >> 24312388 |
Mengge Zhou1, Min Jiang, Xuhui Ying, Qingxin Cui, Yanqi Han, Yuanyuan Hou, Jie Gao, Gang Bai, Guoan Luo.
Abstract
Lotus nelumbo (LN) (Nelumbo nucifera Gaertn.) is an aquatic crop that is widely distributed throughout Asia and India, and various parts of this plant are edible and medicinal. It is noteworthy that different organs of this plant are used in traditional herbal medicine or folk recipes to cure different diseases and to relieve their corresponding symptoms. The compounds that are contained in each organ, which are named based on their chemical compositions, have led to their respective usages. In this work, a strategy was used to identify the difference ingredients and screen for Nuclear-factor-kappaB (NF-κB) inhibitors with anti-inflammatory ability in LN. Seventeen main difference ingredients were compared and identified from 64 samples of 4 different organs by ultra-performance liquid chromatography that was coupled with quadrupole/time of flight mass spectrometry (UPLC/Q-TOF-MS) with principal component analysis (PCA). A luciferase reporter assay system combined with the UPLC/Q-TOF-MS information was applied to screen biologically active substances. Ten NF-κB inhibitors from Lotus plumule (LP) extracts, most of which were isoquinoline alkaloids or flavone C-glycosides, were screened. Heat map results showed that eight of these compounds were abundant in the LP. In conclusion, the LP extracts were considered to have the best anti-inflammatory ability of the four LN organs, and the chemical material basis (CMB) of this biological activity was successfully validated by multivariate statistical analysis and biological research methods.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24312388 PMCID: PMC3843740 DOI: 10.1371/journal.pone.0081971
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Results of PCA and the BPI chromatograms of different organs of LN.
BPI chromatograms (A), score plots (B) and Loading plots (C) in the positive and negative ESI mode are shown. The peak numbers, significance values and relative content (MAX.) are consistent with those in Table 1(A and B).
MS/MS data from ESI-MS and identification of the PCA results and the bioactive compounds of LP in positive mode (A) and MS/MS data from ESI-MS and identification of the PCA results and the bioactive compounds of LP in negative mode (B).
|
|
|
|
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.3687 | 6.00 | Higenamine | 272.1256 | 272[M+H] | C16H17NO3
| Benzylisoquinoline alkaloid |
| ||||
| 2 | 0.4061 | 7.50 | Lotusine | 314.1801 | 314[M+H] | C19H24NO3
+
| Benzylisoquinoline alkaloid |
| ||||
| 3 | (NS | 8.60 | 4’-methylcoclaurine | 298.1458 | 298[M+H] | C18H21NO3
| Benzylisoquinoline alkaloid |
| ||||
| 6 | 0.4206 | 14.07 | Isoliensinine | 611.3080 | 568[M+H-CH3-CO] | C37H42N2O6
| Bisbenzylisoquinoline alkaloid |
| ||||
| 7 | 0.2860 | 15.14 | Liensinine | 611.3107 | 568[M+H-CH3-CO] | C37H42N2O6
| Bisbenzylisoquinoline alkaloid |
| ||||
| 8 | 0.2421 | 17.44 | Neferine | 625.3271 | 582[M+H-CH3-CO] | C38H44N2O6 | Bisbenzylisoquinoline alkaloid |
| ||||
| 9 | 0.4742 | 19.32 | Nuciferine | 296.1649 | 265[M-NH2CH] | C19H21NO2 | Aporphine alkaloid |
| ||||
| 10 | 0.5091 | 22.90 | β-sitosterol | 415.6931 | 415[M+H]+,396[M+-H2O] | C29H50O | Steroid |
| ||||
| 12 | 0.3395 | 19.17 | roemerine | 280.1298 | 249[M-NH2CH3] | C18H17NO2 | Aporphine alkaloid |
| ||||
| 13 | 0.2110 | 12.70 | 4’-Methyl-N-methylcoclaurine (MMC) | 314.1735 | 299[M+H-CH3] | C19H23NO3 | Benzylisoquinoline alkaloid |
| ||||
| 14 | 0.2320 | 13.21 | Armepavine | 314.1730 | 283[M-NH2CH3] | C19H23NO3 | Benzylisoquinoline alkaloid |
| ||||
| 16 | 0.2474 | 15.07 | O-nornuciferine | 282.1489 | 251[M-NH2CH3] | C18H19NO2 | Aporphine alkaloid |
| ||||
|
|
|
|
|
|
|
|
|
|
| |||
| 4 | 0.3195 | 10.87 | Apigenin-6-C-α-L-glucopyanosyl-8-C-β-D-glucopyranoside(AGG) | 593.1747 | 503[M-H-C3H6O3]-,473[M-H-C4H8O4]-,443[M-H-C5H10O5]-,383[M-H-C4H8O4-C4H8O4]-,353[M-H-C4H8O4-C5H10O5]-,268[M-H-C6H11O5-C6H11O5]- | C27H30O15 | Flavone C-glycoside |
| ||||
| 5 | 0.3981 | 13.18 | Apigenin-6-C-α-L-arabofuranosyl-8-C-β-D-glucopyranoside(AAG) | 563.1326 | 563[M-H]-,443[M-H-C4H8O4]-,413[M-H-C5H10O5]-,268[M-C6H11O5-C5H9O4]- | C26H28O14 | Flavone C-glycoside |
| ||||
| 11 | 0.2701 | 15.28 | Luteoloside | 447.0984 | 447[M-H]-,285[M-H-C6H11O5]- | C21H20O11 | Flavone glycoside |
| ||||
| 15 | 0.4147 | 18.56 | unknown | 727.1881 | 607,591 | / | / |
| ||||
| 17 | 0.2907 | 14.75 | Hirsutrin | 463.0750 | 927[2M-H]-,301[M-H-C6H10O5]- | C21H20O12 | Flavone O-glycoside |
| ||||
| 18 | 0.2360 | 14.30 | Hyperin | 463.0771 | 927[2M-H]-,301[M-H-C6H10O5]- | C21H20O12 | Flavone O-glycoside |
| ||||
Verification of standard products NS: no significance
Figure 2Effects of different organs of LN on NF-κB inhibition (A) and the heat map (B).
A: The levels of NF-κB in TNF-α stimulated HEK 293 cells. Values are presented as the mean ± SEM, n = 5 for each group. **p <0.05 vs the group that was treated with TNF-α in the absence of extracts and drugs, ## p < 0.05 vs the Control group; B: The relative content of each marker ingredient in different organs. Zero content was expressed as red and largest content (100%) as green.
Figure 3UPLC-Q-TOF/MS and bioactivity analyses of LP.
(A) UPLC-UV chromatograms of LP TIC data in (B) the positive and (C) negative ESI modes. Bioactivity chromatograms were obtained via the dual-luciferase reporter assay system for (D) NF-κB inhibition. NF-κB inhibition values are presented as the mean ± SEM, n = 5 for each group. The peak numbers are consistent with those in Table 1(A and B).
Figure 4Chemical structures of the bioactive compounds in the LP.
Figure 5Confirmation of the bioactive compounds from the LP in TNF-α-induced BEAS-2B cells.
(A) Effects of the potential NF-κB inhibitors by the dual-luciferase reporter assay system, effects of the representatives of four NF-κB inhibitor types on (B) IL-6 and (C) IL-8 expression. Each bar represents the mean ± SEM. n = 5, **p < 0.05 vs the group that was treated with TNF-α in the absence of extracts and drugs, and ## p < 0.05 vs the Control group. One (*) or two (**) asterisks indicate p < 0.05 or p < 0.01, respectively.
Figure 6The organ-active-ingredients application for LN organs.